Management of patients with hypogonadism is dependent on the underlying cause. Whilst
functional hypogonadism presenting as delayed puberty in adolescence is relatively …

Male delayed puberty is common, affecting up to 3% of the population. Management of
patients with pubertal delay is dependent on the underlying cause. The main differential …

Background/purpose Few studies have evaluated craniofacial growth in boys and girls with
idiopathic short stature (ISS) during growth hormone (GH) treatment. The aim of this study …

Objectives Growth hormone (GH) therapy's capacity to increase height velocity and height at
the end of the study in children with idiopathic short stature (ISS) is controversial. We aimed …

Background: Heterozygous loss-of-function mutations in the natriuretic peptide receptor B
gene (NPR2) are responsible for short stature in patients without a distinct phenotype. Some …

Resumen Entre el 0, 6 y el 2, 3% de los niños sanos tienen talla baja. Sin embargo, con la
evaluación clínica y analítica estándar no se alcanza un diagnóstico en un alto porcentaje …

Background: In recent years, several studies have been published showing different
responses to growth hormone (GH) treatment in idiopathic short stature children. The aim of …

BACKGROUND: Subjects with hypo-or hypergonadotropic hypogonadism need hormone
replacement therapy (HRT) to initiate puberty and maintain it with a normal hormonal status …

Craniofacial and dental morphology is influenced by different circulating hormones, but it is
of particular importance that there is growth hormone (GH) in normal craniofacial and teeth …

Background/Aims: Idiopathic short stature (ISS) is defined as short stature of unknown origin.
Responses to growth hormone (GH) in children with ISS are highly variable and dose …